论文部分内容阅读
目的比较腺病毒(Adenovirus,Ad)载体乙型肝炎病毒(HapotitisBvirus,HBV)疫苗鼻腔黏膜、皮下注射接种小鼠免疫效果。方法以腺病毒为载体、以HBVpreS2/S为目的基因构建重组疫苗,然后将重组疫苗分别鼻黏膜和皮下接种BALB/c小鼠,与阴性对照组(载体对照组、生理盐水对照组)比较接种重组疫苗35、72d的免疫效果。结果鼻腔接种AdHBV疫苗组动物在72d时血清抗体终末效价为1/2470,同时可提高NK细胞杀伤能力和干扰素γ、IL2含量升高。皮下注射AdHBV在免疫35d和72d、1∶200血清稀释度均未测到阳性抗体(A值,P/N值<21)。结论重组疫苗黏膜接种诱导小鼠产生特异抗体和细胞免疫反应高于皮下接种途径。
Objective To compare the immune effects of intranasal mucosa with subcutaneously injected Hapotitis virus (HBV) vaccine against Adenovirus (Ad) in mice. Methods Recombinant vaccine was constructed with adenovirus as carrier and HBVpreS2 / S as target gene. BALB / c mice were inoculated nasal mucosa and subcutaneously into the BALB / c mice respectively and inoculated with negative control group (vector control group and saline control group) Recombinant vaccine 35, 72d of the immune effect. Results The final antibody titer of serum antibody in AdHBV vaccinated group was 1/2470 at the 72th day. At the same time, the cytotoxicity of NK cells and the increase of interferon γ and IL2 were increased. Subcutaneous injection of AdHBV at 35 d and 72 d after immunization, serum dilution of 1: 200 were not detected positive antibodies (A value, P / N value <21). Conclusion Recombinant vaccine mucosal inoculation induced specific antibodies and cellular immune response in mice than in subcutaneous inoculation.